Avivagen Inc. (TSXV:VIV) - sind wir sind jetzt auf den Hund gekommen? - 500 Beiträge pro Seite

[Ahorne]

Hallo Leute

Intressante Aktie aus meiner Sicht.

Homepage: http://www.chemaphor.com/index.php

Aktie: http://tmx.quotemedia.com/quote.php?qm_symbol=cfr&locale=EN
Total Shares: 83,814,082


Präsentation: http://www.chemaphor.com/investors/Chemaphor%20Investor%20Pr…

Building its business in 3 stages by addressing unmet needs in multi-billion dollar animal and human health markets:

1.Companion Animal Health: Our product already on the market generating sales > $500M market

2.Food Animals: Alternative to antibiotic growth promoters in food animal production (food safety) > $1B market

3.Human Health & Wellness: Immune boosting supplements > $1B market


Produkt:

We invented, developed and own a unique technology

Our Product is called OxC-beta
•Mixture derived from ß-carotene nutrient
•New, basic scientific discovery
•Patent protected, first scientific publications soon Unique combination of

immune benefits
•Primes innate immune system
•Anti-inflammatory

[Ahorne]

Antwort auf Beitrag Nr.: 42.937.151 von Ahorne am 21.03.12 18:30:48

Produkt schon auf dem Markt

u.a. Partnerschaft mit Teva Animal Health
Teva Animal Health, a division of Teva Pharmaceuticals (Market Cap: $38 Billion)

Pet Health & Wellness

Companion Animals OxC-beta Supplement for Dogs
Oximunol Chewable Tablets


•A natural, high-quality ingredient, once-a-day, chewable tablet for your dog (available now)
•Clinical and scientific studies have shown:
–supports immune function
–improves mobility
–enhances gastrointestinal health
–optimizes coat quality
–reduces shedding
•Launched in Canada, next market is US
•Seeking additional international distribution agreements

[Ahorne]

Antwort auf Beitrag Nr.: 42.937.321 von Ahorne am 21.03.12 18:58:27

"Teva Animal Health" News:

AVIVAGEN ANNOUNCES U.S. DISTRIBUTION AGREEMENT
http://www.chemaphor.com/news/CFR%20February%2015%202012.pdf

&

Avivagen Homepage

(Avivagen, a Canadian company is the wholly‐owned commercial subsidiary of Chemaphor, Inc.)
http://www.avivagen.com/

Avivagen Animal Health Inc. is dedicated to developing science-based, natural health products for companion animals that are proven in clinical trials and offering veterinarians alternatives to traditional treatments.

[Ahorne]

Antwort auf Beitrag Nr.: 42.937.514 von Ahorne am 21.03.12 19:23:59

2 Anwendungsmöglichkeit:

Food Production & Safety

Das Problem:

Resistente Bakterien sorgen zunehmend für Probleme
Multiresistente Keime sorgen in Spitälern zunehmend für Probleme. Auch wenn Antibiotikaresistenzen nicht neu sind, ist das Problem grösser als angenommen – auch die Landwirtschaft gerät zunehmend in Zugzwang.
http://www.schweizerbauer.ch/htmls/artikel_28031.html




Lösung?

Food Animals OxC-beta Alternative to Antibiotics

Competitive Advantages
•Non-antibiotic, non-hormonal – no risk to humans
•Delivered via animal feed – no bacterial resistance
•Animals grow faster, use less food
•Cost competitive with antibiotics
•Reduces costs to produce food, effective & safe
•IP protected until 2025

[Ahorne]

Antwort auf Beitrag Nr.: 42.937.151 von Ahorne am 21.03.12 18:30:48

3. Anwendungsmöglichkeit:

Human Market: More Potential
•OxC-beta can be integrated into numerous nutritional supplements, functional foods, and skin care products
–Represents a total market size > $20 billion
•Early proof-of-concept data has identified a potential immune boosting supplement to enhance overall health
•Long-term goal to replicate a strategy like Afexa (TSX:FXA)’s COLD-FX®
–Afexa is being bought by Valeant Pharmaceuticals for $88 million in cash (announced 09/11)

[zyperus]

Antwort auf Beitrag Nr.: 42.937.672 von Ahorne am 21.03.12 19:51:27

hallo mein lieber,
kann ich nicht widerstehen hier bei dir
zu schreiben. ich habe ja einige zeit
benötigt deinem tempo zu folgen....

respekt, solch einen wert muss man finden.dein spektrum
muss enorm sein....neben deiner rohstoff affinität...

das ließt sich sehr, sehr interessant.
ich habe ein großes faible zu diesen kleinen
nischenwerten....lese mich ein. melde mich hier.

gruß
zyperus

[manffreddoo]

Hallo Ahorne,
cool...wie bist du nur auf diesen Wert gekommen....liest sich interessant....bei den Problemen mit Antibiotika...wenn Chemaphor hier ne Lösung anbietet...in der Tat, das wär ein Ding ....
M.

[Ahorne]

Antwort auf Beitrag Nr.: 42.938.410 von manffreddoo am 21.03.12 22:52:27

Guten Morgen manffreddo & zyperus

Ja, der Wert sieht auf den ersten & zweiten Blick wirklich intressant aus.
Wie ich auf den Wert gekommen bin - erstens hat Rundschau eine Sendung von dem Schweizer Fernsehen eine grosse Serie über Resistente Bakterien ausgestrahlt. Und gestern habe ich Stockhouse ein Banner von der Company gesehen. Zufall

Die Frage ist, welche Konkurzenz auf dem Markt ist und ob das Produkt von den Bauern angenommen wird/muss.

Ein Produkt - "Kaugummi für Hunde" ist schon auf dem Markt mit einem starken Partner.

Danke Zypreus für das Kompliment Ja, mein Allgemeinwissen ist ich so schlecht.

Lasst uns noch ein paar Fakten sammeln...

[Ahorne]

gute Übersicht was derzeit bei Chemaphor läuft:

CHEMAPHOR PROVIDES CORPORATE UPDATE
February 10, 2012
http://www.chemaphor.com/news/CFR%20February%2010%202012.pdf

ps.

Dieser Punkt isch schon abgearbeitet

Progress Towards a Distribution Agreement for Oximunol™ Chewables in the US
Securing a US distribution agreement for Oximunol™ will be a significant milestone for Chemaphor, providing access to the largest consumer base in the world, without incurring any increase in overhead or internal sales, marketing or advertising costs. -> TEVA

[Ahorne]

Antwort auf Beitrag Nr.: 42.940.579 von Ahorne am 22.03.12 12:46:00

Diese Punkte können aus meiner Sicht relativ schnell erreicht werden.
(Ersatz von Antibiotika wird aus meiner Sicht ne langwierige Geschichte, hat aber viel Fanatsie)

Companion Animals OxC-beta Supplement for Dogs
Oximunol Chewable Tablets

- Ausweitung des Gebietes ausserhalb Kanada & USA

- Ausweitung auf Katzen & Pferde

- und für mich das wichtigste: Ausweitung (neue Produktline) auf Verkauf an Endkunden.
(bis jetzt kann man das Produkt nur über Tierartz beziehen)


Oximunol™ Distribution Agreements in International Markets
As part of its commercial strategy, Chemaphor has begun discussions with a number of multinational companies and is examining a variety of strategic channels to market Oximunol™ Chewables in various overseas markets.

Oximunol™ Products for Other Companion Animals
Chemaphor is beginning safety tests of OxC-beta in cats in preparation for launching a supplement for cats that will be the counterpart of Oximunol™ Chewables for dogs. Work is also underway to evaluate the benefit of OxC-beta for performance horses.

Development of a Product Line of Pet Supplements for Direct-to-Consumer Sales
Buoyed by the response of pet parents and their dogs to the various benefits of Oximunol™ Chewables, as shown by direct evaluations (e.g., improved coat and skin condition, increased mobility and energy in older dogs), Chemaphor is preparing to develop a branded line of specialized pet products based on OxC-beta. These will be introduced in stages and marketed directly to consumers via the internet, specialty pet stores and pet boutiques.

[Ahorne]

Avivagen Presents Canine Supplement at PEI Home Show

Tuesday, March 27, 2012
http://www.theglobeandmail.com/globe-investor/news-sources/?…

[Ahorne]

Antwort auf Beitrag Nr.: 42.960.969 von Ahorne am 27.03.12 15:05:04

Fotos von der Ausstellung und Produkt:
http://www.facebook.com/photo.php?fbid=410096629003890&set=a…

[Ahorne]

Chemaphor Inc. Status Update on Non-Antibiotic OXC-Beta Feed Additive

Thursday, March 29, 2012
http://www.theglobeandmail.com/globe-investor/news-sources/?….

[Ahorne]

Zitat von Ahorne: Chemaphor Inc. Status Update on Non-Antibiotic OXC-Beta Feed Additive

Thursday, March 29, 2012
http://www.theglobeandmail.com/globe-investor/news-sources/?….

Intressant in diesem Zusammenhang:

Atlantic Veterinary College
University of Prince Edward Island
AVC Research Report
Celebrating 25 years · 1986-2011
http://avc.upei.ca/files/avc/AVCResearchReport.pdf

u.a.

Discovery and Innovation

Industry Chair in Swine Research
Dr. Daniel Hurnik is working with
private industry to improve the growth
of livestock, using non-antibiotic feed
additives. Dr. Hurnik’s research with
young pigs demonstrates that a low
amount of OxC-beta added to regular
swine feed helps support immune
function, which can result in better
overall health, improved growth and
feed utilization. OxC-beta is a proprietary,
concentrated mixture of fully oxidized
carotenoids owned by Chemaphor Inc.

[Ahorne]

Kein Wert für schwache Nerven:
http://stockcharts.com/h-sc/ui?s=CFR.V

[Ahorne]

Good new article in the New York Times on antibiotics in animal use...


U.S. Tightens Rules on Antibiotics Use for Livestock

New York Times -> GARDINER HARRIS
Published: April 11, 2012
http://www.nytimes.com/2012/04/12/us/antibiotics-for-livesto…

[Ahorne]

Chemaphor Pursuing Partnering Initiative to Commercialize Non-Antibiotic Feed Additive Alternative to Improve Productivity and Safety in Food-Producing Animals

Tuesday, April 17, 2012

http://www.theglobeandmail.com/globe-investor/news-sources/?…

[boersehp]

Hi Ahorne, angelockt durch die 33% werd ich mir diesen wert auch ein wenig genauer betrachten, habe da auch schon in ein paar links von Dir reingelugt....

Sehr spannend Vergleich mit Afexa okay Ziel marketcap von 90 Millionen allerdings bei 15 Mio Quartalsumsatz, Du hast doch bestimmt schon tiefer in die Zahlen reingeschaut?
Haben die Schulden ? oder ist bisher alles über private placement finanziert und gibts schon irgendsowas wie revenuezahlen....

Danke HP

[Ahorne]

Antwort auf Beitrag Nr.: 43.050.522 von boersehp am 17.04.12 17:38:35

Hallo HP

Ja, von solchen Verkäufen kann Chemaphor derzeit nur träumen.

laut letzten Finanzbericht keine Schulden.

lg. A

[Ahorne]

Chemaphor Releases Business Overview Video
http://www.theglobeandmail.com/globe-investor/news-sources/?…
Wednesday, April 18, 2012


OTTAWA, ONTARIO, April 18, 2012 - Chemaphor has released a video summary presentation of its multi-product business development platform based on its novel OxC-beta technology. The presentation, which may be viewed at the Chemaphor website (www.chemaphor.com), is made by CEO David Hankinson who describes how the unusual combination of immune properties of OxC-beta can benefit companion animals, food-production animals and humans globally.

About OxC-beta

OxC-beta is Chemaphor's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

[Ahorne]

Chemaphor Receives First U.S. Order For Oximunol (tm) Chewables

http://www.theglobeandmail.com/globe-investor/news-sources/?…
Thursday, April 19, 2012

OTTAWA, ONTARIO, April 19, 2012 - Avivagen Animal Health Inc., the commercial arm of Chemaphor Inc. (TSXV:CFR), is pleased to announce that it has received the first order for Oximunol(TM) Chewables for dogs for the veterinary market in the U.S. This follows on from the recent announcement of its distribution agreement for Oximunol(TM) Chewable Tablets in the U.S. and accreditation from the National Animal Supplement Council of Oximunol(TM) companion animal supplement products in the U.S. David Hankinson, CEO of Chemaphor, said "This achievement of an order for product is a major milestone in Chemaphor's strategy to expand into the International market with products that can improve the quality of life for companion animals. We are pleased by the size of this first purchase order and are excited that Oximunol(TM) Chewable Tablets, which has been so well-received by dog owners in the Canadian market, finally will become available to dog owners in the US through their veterinarians." Dave Hankinson also added, "This is a great first step in our international commercial efforts and brings our investors validation of demand for our Oximunol(TM) Chewables, while we seek distribution agreements in other territories and also aim to bring follow-on products to market."

About Oximunol(TM) Chewables - Optimized health in a chewable tablet

Oximunol(TM) is a scientifically formulated chewable tablet that contains Chemaphor's proprietary, patented active ingredient OxC-beta. OxC-beta is a highly concentrated version of oxidized derivatives of carotenoids that are found naturally and extensively in the plant world in minute amounts. It is currently available for dogs of all ages. Oximunol(TM) Chewables work with a dog's own immune system to optimize overall health and well-being, including:

+Promotes and supports healthy joint function

+Promotes and maintains normal mobility

+Enhances healthy condition of skin and coat

+May help discomfort associated with normal daily activity

+Leads to maintenance of normal intestinal function

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

About Avivagen

Avivagen, a wholly-owned subsidiary of Chemaphor, is dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com

[Ahorne]

Chemaphor Announces Option Grants
http://www.stockhouse.com/financialtools/sn_newsreleases.asp…

[uall]

Hallo Ahorne,
habe diesen Thread heute morgen bei der allwöchentlichen Durchschau durch das Forum entdeckt, und fand Chemaphor erst mal sehr interessant. Gerade der potentielle Einsatz als Antibiotika-Ersatz in der Viehhaltung hat mich aufhorchen lassen. Habe nun ein bisschen recherchiert aber ich konnte keinerlei Studien zu den Wirkstoffen finden ... Es heisst aber schon Anfang 2010 (http://www.reuters.com/article/2010/02/01/idUS209489+01-Feb-…) dass Ergebnisse in einem Journal mit Peer-Review veröffentlicht werden sollen, was bis heute nicht passiert ist. Das ist natürlich sehr ernüchternd, weil die einzige Studie zu Oximunol z.B. von Chemaphor selbst ist, die ich als nicht sehr repräsentativ empfinde (geringe Population, subjektive Bewertungskriterien, Ergebnisse: "besseres Fell" und "höhere Aktivität"). Ich fand ein paar konzeptuelle Arbeiten von G. Burton selbst, die sich zwar interessant lesen, aber keinerlei Schlüsse zur Effizienz bzw. Wirksamkeit ableiten lassen. Hast du in dieser Richtung irgendetwas "handfestes" gefunden? So ist es für mich erstmal nur eine "interesting story" ...

Grüße und danke für diese Ausgrabung

[uall]

Eine kritische Meinung zu Oximunol (von 2010, aber viele Punkte sind immernoch aktuell): http://skeptvet.com/Blog/2010/02/oximunol-the-latest-in-mark…

Bitte nicht falsch verstehen, ich finde Chemaphor wirklich sehr interessant, aber man muss sich selbst immer hinterfragen, und gerade kritische Meinungen bringen einen hier meist sehr viel weiter

[Ahorne]

Zitat von uall: Eine kritische Meinung zu Oximunol (von 2010, aber viele Punkte sind immernoch aktuell): http://skeptvet.com/Blog/2010/02/oximunol-the-latest-in-mark…

Bitte nicht falsch verstehen, ich finde Chemaphor wirklich sehr interessant, aber man muss sich selbst immer hinterfragen, und gerade kritische Meinungen bringen einen hier meist sehr viel weiter

Hallo uall

Danke für Dein Beitrag! Ja, kritische Kommentare sind herzlich willkommen.

Ob und vorallem in welchem Masse der Oximunol aufnimmt ist die grosse Frage und hier das grösste Risiko aus meiner Sicht. Der geringe Unternehmenswert zeigt an, dass entweder der Markt nicht an das Produkt glaubt, oder das Produkt unbekannt ist. Management muss beweisen, das es funktioniert.

Risiko bei Chemaphor ist derzeit eher gross.

[Ahorne]

Chemaphor Inc. Completes Private Placement
http://www.theglobeandmail.com/globe-investor/news-sources/?…

Wednesday, May 16, 2012

(via Thenewswire.ca)

OTTAWA, ONTARIO, May 16, 2012 - Chemaphor Inc. (TSX Venture Exchange: CFR), today announced that it has issued a total of 6,101,715 common shares and 6,101,715 common share purchase warrants for gross proceeds of $427,120.05 through a non-brokered private placement.

This private placement involved the sale of units, each comprised of one common share and one common share purchase warrant, for a unit price of $0.07. Each warrant entitles the holder to acquire one common share of Chemaphor at an additional purchase price of $0.10 per share for three years from closing.

In connection with the private placement Chemaphor paid a total of $3,280 in cash commission and warrants to acquire 46,857 common shares to agents involved in the sale of units. The warrants issued to such agents have the same terms as the warrants issued to subscribers in the private placement.

The net proceeds of the proposed offering will be used to fund working capital and research and development expenditures and for general corporate purposes.

The securities issued under this private placement are and will be subject to restrictions on transfer, including a hold period ending four months after issuance. The private placement remains subject to TSX Venture Exchange approval. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities.

[Ahorne]

Chemaphor Inc. to Change Name to Avivagen Inc.
http://www.theglobeandmail.com/globe-investor/news-sources/?…

Friday, May 25, 2012

(via Thenewswire.ca)

Ottawa, Ontario, May 25, 2012 - Chemaphor Inc. (TSX Venture Exchange: CFR) (the "Company") announced that it has filed articles of amendment to change its name to "Avivagen Inc." effective today. The Company's shareholders approved the change of name at a shareholder meeting held on April 27, 2011. The TSX Venture Exchange (the "Exchange") previously provided its conditional acceptance of the name change and the Company has today submitted additional materials to the Exchange in request of final approval. Assuming all is satisfactory to the Exchange, the Company expects to begin trading on the Exchange under the new name and the symbol "VIV" at opening of trading on or about Wednesday May 30, 2012.

In making the transition from a purely research and development enterprise to a commercial organization, the Company previously created a fully-owned subsidiary, Avivagen Animal Health Inc., expressly for the conduct of sales and marketing support activities. The new name, which has been well received, was chosen to reflect the natural product focus of the Company and the wide opportunities available for its OxC-beta technology in the animal health field.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

[Ahorne]

AVIVAGEN (formerly Chemaphor) Featured on Business Television (BTV)
http://www.theglobeandmail.com/globe-investor/news-sources/?…

Tuesday, May 29, 2012

(via Thenewswire.ca)

Ottawa, Ontario, May 29, 2012 - Avivagen Inc. (formerly Chemaphor Inc.; TSXV: CFR) (the "Company") announces that the Company was featured on Business Television (BTV) on May 26 and May 27, 2012, through segments on BNN and Fox Business News, among others. The segment highlighted Avivagen's recently launched supplement for companion animals. BTV is a half-hour weekly business news program that profiles emerging publicly traded companies across Canada and the U.S.

The Company was featured on BTV on the following channels:

In Canada:

-BNN - Saturday, May 26 @ 8:00pm EST & Sunday, May 27 @ 9:30am EST

-Bell Express Vu - Saturday, May 26 @ 8:00pm EST & Sunday, May 27 @ 9:30am EST

In the U.S.:

-Fox Business News - Sunday, May 27 @ 5:00pm EST

-America One - Saturday, May 26 @ 10:00am EST (www.americaone.com)

-Biz Television Network - Saturday, May 26 @ 1:30pm; Sunday, May 27 @ 1:30pm;

Wednesday, May 30 @7pm; Thursday, May 31 @ 10:30am; and Friday, June 1 @ 6:30pm EST

(www.biztv.com)

A link to the feature will be available on the Company's website (www.chemaphor.com) and is available here:

-http://www.b-tv.com/features/watch-now.html?clip=CEOChemapho… v

About Avivagen (formerly Chemaphor)

Avivagen, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

[Ahorne]

AVIVAGEN BEGINS TRADING UNDER NEW SYMBOL “VIV”
http://www.chemaphor.com/news/CFR%20May%2030%202012.pdf

[Popeye82]

noch zu früh, aber Speck ist dran:

Avivagen(V.VIV) focuses health products on companion animal, livestock markets - SHE - Jan 21, 2014
www.stockhouse.com/opinion/interviews/2014/01/21/avivagen-v-…

"The following is a Q&A interview with Avivagen CEO Cameron Groome


Thanks for speaking with us today Cameron, can you tell me about Avivagen?

Avivagen Inc. (TSX: V.VIV, Stock Forum) has discovered a whole new class of natural products that enhance immune function. Our technology is based on the discovery that many of the benefits of commonly-known carotenoid antioxidants only arise after they have been transformed by being fully-oxidized.

This discovery is revolutionary and changes the understandings of the activities of many health supplements, such as beta-carotene, lutein, lycopene, astaxanthin and others – in fact, most of the best known antioxidant health products.


What kind of results have you seen from your products?

We are focused on developing the animal health applications of our technology, as this is a faster route to regulatory approvals and product sales. In animal trials, we’ve seen our OxC-beta maintain or enhance the health of both companion animal and livestock species. This includes dogs, chickens, pigs, cattle and even fish.

Notably, we’ve demonstrated meaningful benefits to the skin, coat and mobility of dogs. We’ve also shown enhanced growth (poultry & swine), improved feed conversion efficiency (poultry & swine) and disease protection (poultry and cattle). These benefits are very important to pet parents and economically relevant to livestock producers.


Who do you sell to?

We sell three products based on our technology and each has a different target market. Oximunol Chewable tablets for dogs are sold to veterinarians by Bayer’s animal health sales force. Avivagen is test marketing its second companion animal product, Vivamune Health Chews, which is a direct-to-consumer product in the United States. Our third product is OxC-beta premix for livestock, which we have begun to sell to large livestock and feed producers in Asia.


Is your process proprietary?

Avivagen transforms these compounds into a mix of naturally-occurring and immunologically-active bio-polymers. This process and its resulting products are unique and proprietary to Avivagen. Our principal product, OxC-beta, has been shown to enhance the body’s ability to recognize and respond to bacterial infections, while also reducing inflammation.

This is a very desirable mix of product activities and may be applicable to some important health issues.


Can you tell us about the partnership you have with Bayer?

Bayer Animal Health is our partner for United States distribution and marketing one of our products, Oximunol Chewable Tablets for dogs. We are very pleased to have a leading animal health company as our partner for this new companion animal health supplement. Bayer has taken delivery of a stocking order of Oximunol (November, 2013) and we’re looking forward to seeing results from their marketing efforts in 2014.


What are your plans for the first half of 2014?

My latest letter to shareholders highlights the work we’re doing in Asian livestock markets. Specifically that we’ve built relationships in six of the world’s largest livestock producing and consuming nations - working with potential customers to help them field test OxC-beta in their species of interest. We’re hopeful that positive results from such trials will lead to material product orders, perhaps as soon as the first half of 2014. We’ll disclose further national registrations and sales from Asian countries as they occur.


Does the company generate revenues?

Yes. Currently, corporate revenues are in the hundreds of thousands per year – from a combination of companion animal product sales to the United States, livestock sales to Asia and the provision of chemistry services. These revenues are not yet enough to cover our operating costs of about $2.0 million a year. We estimate that we need about $3.5 million in top-line revenues to break-even, a number that is achievable from penetrating even a tiny portion of our companion animal and livestock markets. Our overall sales potential is large enough for us to become very profitable.


Why should an investor consider paying more attention to Avivagen?

We have valuable and proprietary products directed to the large companion animal and livestock markets that we’re positioning to become big winners:

- In companion animals, we have multiple products and marketing channels in the United States - the world’s largest consumer market.
- For livestock, relationships with leading companies in some of the world’s largest livestock production markets and for the most commercially important species.


We expect 2014 to be a pivotal year and are committed to developing Avivagen into a pre-eminent creator of products for companion and food animals. Our company is skilled in validating product applications, creating commercially-viable product formulations, managing logistics and building stakeholder relationships. We are employing these strengths to generate exceptional and sustained value for our shareholders.


Disclosure: Avivagen is a Stockhouse client. "

[Popeye82]

Avivagen Announces Swine Trial Agreement with National Institute of Animal Sciences, for Vietnam - Mar 25, 2014
http://app.quotemedia.com/quotetools/newsStoryPopup.go?story…

"Ottawa, ON / TNW-ACCESSWIRE / Mar 25 2014 / - Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces an agreement with the National Institute of Animal Sciences for Vietnam to conduct a trial of OxC-beta as a non-antibiotic growth promoter for swine.

The trial will test the efficacy of OxC-beta to maintain and enhance the health and growth of pigs across their full post-wean growth cycle. The response to the addition of OxC-beta in the diet will be recorded via measurement of a series of health and commercial measures. Such measures will include, but not be limited to, weight gain, feed conversion efficiency, incidence of diarrhea and disease-related mortality.

The trial is entitled "Evaluation of OxC-beta as a Growth Promoting Health Supplement for Swine." Its testing of OxC-beta will include five study arms: three feeding-levels of OxC-beta, a negative control and a commercial antibiotic growth promoter (AGP) control. The trial was designed by Professor La Van Kinh of the National Institute of Animal Sciences for Vietnam, Professor William Riley of Jinan University of Guangzhou, China and Avivagen executives. The trial, which will be conducted by Professor Kinh at the Institute and is expected to be completed before the end of calendar 2014, is intended to support registrations for this usage.

Cameron Groome, CEO and President, commented on Avivagen's objectives with respect to this trial "Previously, OxC-beta was tested for a shorter dosing period in weaned piglets. While the results of that Canadian piglet study were very positive, they have not been reconfirmed by way of another study, nor have the benefits of OxC-beta been measured for older swine. This trial should accomplish both those goals, along with helping to establish the feeding levels that are most effective and economic."

Cameron also commented on other ongoing and planned studies of OxC-beta "This study is the first Avivagen-sponsored trial of OxC-beta to be conducted in 2014. While there are also multiple trials being designed and run directly by our prospective customers, it is the Avivagen-sponsored studies that will provide publishable results to support multiple national product registrations. Unlike Avivagen-sponsored trials, any positive results of customer-sponsored OxC-beta trials might not be reported other than by way of product sales."

As a country, Vietnam is the world's sixth-largest user of swine feed - estimated by Pig International magazine at 8.75 million metric tons of feed in 2012. In comparison, Canada ranks as number seven in 2012, using 7.36 million metric tons. Avivagen's pricing for the addition of OxC-beta to swine feed will be set in dollars per ton of feed and dependent on efficacy and the selected level of addition. Pricing of OxC-beta supplementation is expected to be competitive with other growth-promoting feed additives, including antibiotic and non-antibiotic options.


About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen's targeted markets include Livestock Productivity and Pet Wellness.

The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. More information can be found at www.avivagen.com.


About OxC-beta

Avivagen's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research and study results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

The commercial products of Avivagen are OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM) Chewables.


About OxC-beta for Livestock

OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with producer-developed protocols. In past studies, OxC-beta has been shown to support health and growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.


About Vivamune(TM) Health Chews - For dogs and cats

Vivamune(TM) Health Chews, containing Avivagen's proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.


About Oximunol(TM) Chewables - For dogs

Oximunol(TM) Chewables are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are distributed by Bayer Healthcare LLC and are available through veterinarians for dogs of all ages in the United States.


Forward Looking Statements

This document includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. Statements relating to expectations regarding access to new markets, new or increased revenue streams, Avivagen's ability to secure additional clinical trials and customer relationships and the results of such trials and relationships and Avivagen's intention to identify suitable technology license opportunities are all examples of forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen's products may not gain market acceptance in new markets, new or expected revenue streams may not materialise in the near term or at all, Avivagen may not be able to secure clinical trials or new customer relationships and the results of such trials and relationships may not be favourable. Unless required by law, Avivagen Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.


For more information:

Avivagen Inc.
Cameron Groome
CEO & President
[e-mail]

100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: [phone]
Website: www.avivagen.com

Copyright (C) 2014 Avivagen "

[Popeye82]

Antwort auf Beitrag Nr.: 46.702.269 von Popeye82 am 25.03.14 23:28:15

Zitat von Popeye82: noch zu früh, aber Speck ist dran

Avivagen Announces Poultry Trial Agreement, with Chonbuk National University of Korea - Mar 31, 2014
http://app.quotemedia.com/quotetools/newsStoryPopup.go?story…

"Ottawa, ON / TNW-ACCESSWIRE / Mar 31 2014 / Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces an agreement with Chonbuk National University of the Republic of Korea (South Korea) to conduct a trial of OxC-beta for the prevention of a commercially important poultry disease.

The trial will test the efficacy of OxC-beta for the prevention of morbidity and mortality resulting from the poultry pathogen Clostridium perfringens. This bacterium causes intestinal damage in chickens, leading to reduced feed conversion economics, clinical illness and deaths. It is a troubling bacterial issue in worldwide poultry production and a frequent reason for the prophylactic or therapeutic use of antibiotics in feeds. This bacterium also causes disease in humans; leading to "food poisoning" if ingested and "gas gangrene" if introduced into wounds.

The trial is entitled "Preventative Effect of OxC-beta on Necrotic Enteritis Model with Broiler Chickens." It will have five study arms: testing two clinically and commercially relevant dosages of OxC-beta against two commercial Antibiotic Growth Promoters (AGPs) and a negative control group. The trial will first reconfirm the optimal dose level of OxC-beta in this challenge model and then conduct two parallel repeats of greater statistical-significance.

The trial was designed by Professor Jang Hyung-Kwan, of the College of Veterinary Medicine of Chonbuk National University of Korea, Professor William Riley of Jinan University of Guangzhou, China and Avivagen executives. The trial will be conducted by Professor Jang at Chonbuk and the full protocol is targeted to conclude in the first quarter of calendar 2015.

Cameron Groome, CEO and President, commented on Avivagen's objectives for this trial "Professor Jang has developed an elegant and efficient Clostridial challenge model, and we are pleased to be working with him, Chonbuk and our Korean distributor on this study. It is our hope that this study will provide results to support national registrations for this poultry indication while also emulating the result of a previous trial with OxC-beta against this pathogen."

Cameron also discussed the various studies being established, "Avivagen-sponsored OxC-beta studies are important as they may provide publishable results in support of national product registrations. This second Avivagen-sponsored trial is in addition to trials designed and run by prospective commercial customers, some of which are ongoing and others that are in the planning stages. However, unlike Avivagen-sponsored trials, any positive results of customer-sponsored OxC-beta trials might not be reported other than by way of product sales."


About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen's targeted markets include Livestock Productivity and Pet Wellness.

The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. More information can be found at www.avivagen.com.


About OxC-beta

Avivagen's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research and study results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

The commercial products of Avivagen are OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM) Chewables.


About OxC-beta for Livestock

OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with producer-developed protocols. In past studies, OxC-beta has been shown to support health and growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.


About Vivamune(TM) Health Chews - For dogs and cats

Vivamune(TM) Health Chews, containing Avivagen's proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.


About Oximunol(TM) Chewables - For dogs

Oximunol(TM) Chewables are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are distributed by Bayer Healthcare LLC and are available through veterinarians for dogs of all ages in the United States. "